IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Opera
Advanced lead candidate, MVP-S, in two global Phase 2B clinical trials and enhanced the scientific differentiation of the DPX platformObserved multiple complete clinical responses in relapsed/refractory DLBCL and expect to complete enrollment of stage one in the VITALIZE study in Q2 2023Accelerated enrollment of sta...
Source: pharmiweb.com